OVERSEA CHINESE BANKING Corp Ltd Sells 5,341 Shares of Moderna, Inc. (NASDAQ:MRNA)

OVERSEA CHINESE BANKING Corp Ltd trimmed its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 18.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,504 shares of the company’s stock after selling 5,341 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Moderna were worth $943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of MRNA. State Street Corp grew its position in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares during the period. Amundi lifted its holdings in Moderna by 79.8% in the 4th quarter. Amundi now owns 1,206,273 shares of the company’s stock worth $52,075,000 after buying an additional 535,273 shares during the period. Two Sigma Advisers LP purchased a new stake in Moderna in the 3rd quarter worth approximately $23,825,000. Finally, Douglas Lane & Associates LLC lifted its holdings in Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after buying an additional 298,715 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on MRNA. Citigroup began coverage on Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price objective for the company. Leerink Partners dropped their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Finally, The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and lowered their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and an average price target of $59.60.

Moderna Trading Down 1.4 %

Moderna stock opened at $33.32 on Thursday. The firm has a market cap of $12.86 billion, a price-to-earnings ratio of -3.59 and a beta of 1.86. The stock has a fifty day simple moving average of $35.31 and a two-hundred day simple moving average of $46.45. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.